Does Biosimilar Infliximab Have a Role After Secondary Loss of Response to Its Reference?
Results of a small Greek observational study suggest that biosimilar infliximab may be an effective alternative for the treatment of patients with inflammatory bowel disease (IBD) who have active disease and experienced a loss of response to innovator infliximab (Remicade).
Results of a small Greek observational study suggest that biosimilar infliximab may be an effective alternative for the treatment of patients with inflammatory bowel disease (IBD) who have active disease and experienced a loss of response to innovator infliximab (Remicade).
In a Letter to the Editor of Alimentary Pharmacology & Therapeutics, researchers led by Eleni Orfanoudaki, MD, department of gastroenterology, University Hospital of Heraklion, Heraklion, Greece, reported results of a switch to the biosimilar in 15 patients who failed to respond to other biologics, including the reference infliximab. The patients were switched to the biosimilar at 5 mg/kg on weeks 0, 2, 6, and every 8 weeks thereafter.
The researchers noted that although there have been several studies on switching from the reference to the biosimilar in patients whose IBD is in remission, there have been no published results to date on the use of the biosimilar in patients with active disease and a history of loss of response to the reference.
Thus, they reported what they called “unexpected results” with the use of the biosimilar in patients with active IBD and secondary loss of response to innovator infliximab:
- 8 patients (57%) had a clinical response to the biosimilar by a Harvey Bradshaw Index (HBI) or a Simple Clinical Colitis Activity Index (SCAI) reduction of greater than 2 (P <.05).
- Mean (standard error) erythrocyte sedimentation rate decreased from 51 (6) to 31 (3) mm/h (P =.19).
- Mean C-reactive protein decreased from 10.3 (4.7) to 1.5 (0.4) mg/dL (P <.05).
There were no available measurements of trough levels and anti-infliximab antibodies, however, and only limited endoscopic data for a few patients. Nonetheless, the results of the small observational study suggest that the biosimilar may be an effective alternative for IBD patients with active disease and loss of response to the reference, the researchers conclude. “The underlying mechanism of action of [the biosimilar] in these cases as well as a further validation of this finding could be assessed by future prospective controlled studies including drug pharmacokinetics," they wrote.
Reference
Orfanoudaki E, Drygiannakis I, Koutroubakis I. Letter: Is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator? Aliment Pharmacol Ther.2018. doi:10.1111/apt.14980.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
